Navigation Links
Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
Date:10/22/2013

THOUSAND OAKS, Calif., Oct. 22, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has entered into a definitive agreement with F. Hoffmann-La Roche ("Roche") to acquire Roche's rights to filgrastim and pegfilgrastim in approximately 100 markets, effective Jan. 1, 2014.

Roche has held the rights to filgrastim and pegfilgrastim under license from Kirin-Amgen, Inc. (a joint venture between Amgen and Kirin Holdings Co. Limited, of Japan) in Eastern Europe, Latin America, Asia, the Middle East and Africa since 1989. The franchise generated approximately $200 million in sales in these territories in 2012.

Filgrastim and pegfilgrastim are white blood cell boosting therapeutics used to reduce the risk of infection in patients receiving chemotherapy.  They are marketed by Amgen in the United States and Europe under the trade names NEUPOGEN® and Neulasta®, respectively.

"This agreement will enable Amgen to reach more patients around the world with two of our innovative medicines," said Robert A. Bradway, chairman and chief executive officer of Amgen. "The transaction will also allow us to build experience and capacity in countries that will be important in accelerating future growth of Amgen's pipeline products."

Amgen anticipates this deal will be accretive starting in 2014.

Amgen will begin distributing and selling product as soon as practical in countries where the Company has an existing commercial presence. In countries where Amgen does not have a presence, Roche or its distributors will continue to sell and
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
2. Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgens Acquisition of Onyx
3. Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
4. Amgen To Participate At Citis 8th Annual Biotech Conference
5. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
6. Amgen to Highlight New Data at Upcoming ESC Congress 2013
7. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
8. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
9. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
10. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
11. Amgen Announces Webcast of 2013 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 PharmaEngine, Inc. (TWO:4162) today ... (NASDAQ: MACK ) with its sublicensing partner, ... announced that Baxter has submitted a marketing authorization ... for MM-398 (irinotecan liposome injection), also known as ... pancreas who have been previously treated with gemcitabine-based ...
(Date:5/4/2015)...  Oncobiologics, Inc., a biotherapeutics company focused on ... completed the construction of its GMP commercial launch ... Cranbury, New Jersey . The ... to utilize multiple technologies that enable rapid deployment ... use of the latest single-use technologies, the facility ...
(Date:5/4/2015)... HeartWare International, Inc . (NASDAQ: HTWR ), a leading ... revolutionizing the treatment of advanced heart failure, today announced that ... present at the Bank of America Merrill Lynch 2015 Health ... Thursday, May 14, 2015, at 10:00 a.m. PT (1:00 p.m. ... at the conference will be available via a link on ...
Breaking Medicine Technology:PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2
... a dynamic, service-oriented healthcare technology company has announced an ... and Practice Management software products. This update will enable ... the requirements set forth by the Centers for Medicare ... (Logo: http://photos.prnewswire.com/prnh/20101115/NY01712LOGO ) Currently, SequelMed ...
... capital, a burdensome and uncertain regulatory environment and lack ... the biggest threats to the biomedical industry,s growth over ... surveyed by CHI-California Healthcare Institute, BayBio and PwC US. ... quarters (74 percent) of biomedical industry CEOs surveyed said ...
Cached Medicine Technology:SequelMed Announces ANSI 5010 Upgrade for Its Users 2Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 2Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 3Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 4Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 5
(Date:5/4/2015)... 04, 2015 The U.S. healthcare worker ... join the ranks of senior citizens (1) and 27 ... already over-burdened healthcare system. Additionally, as older healthcare employees ... them. Per the U.S. Census Bureau, the number of ... 75% by 2050 while those 25 to 54 will ...
(Date:5/4/2015)... CA (PRWEB) May 04, 2015 ... is now offering a more comfortable and attractive alternative ... restoration of choice for those who have lost teeth. ... can feel insecure or slip at the worst possible ... eats or talks. They can also painfully pinch or ...
(Date:5/4/2015)... 2015 Pricing Healthcare announces it ... one patient receiving care at St. George Surgical Center ... must be performed by July 15th, 2015, and the patient ... up front and forego the filing of insurance claims). , ... every year, and it devastates more and more individuals and ...
(Date:5/4/2015)... Unlike some camps, the Nike Middle School Running ... goal is to educate first and train second, with a significant ... the young runners are building the knowledge base needed to have ... topics covered include Effort Based Training, Running Heroes, Running Vocabulary, and ... This is not a camp where kids come to run ...
(Date:5/4/2015)... Gettysburg, Pennsylvania (PRWEB) May 04, 2015 ... bicycle and hand cycle ride in the last decade ... after riding 110 miles in two days from the ... national non-profit saw 581 registered disabled and able-bodied participants ... Face of America recognizes and honors the commitment and ...
Breaking Medicine News(10 mins):Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4
... new class of drugs based on a widely used ... the laboratory and in mice, according to researchers. The ... treatment of these tumors. // ,Previous drugs ... same cell targets as hydroxyurea, but had serious side ...
... mantra of the media as dozens of people exposed to ... potent antibiotic. But if the supply dwindles, doctors say other ... previous generation's wonder drug: penicillin. Although alternatives exist, Cipro is ... , // ,It helped that Cipro was the ...
... An experimental anti-cancer drug has shown effectiveness in treating ... report. Researchers say the drug probably acts on many ... for treating other types of cancer. Dr. Antonio Fojo ... colleagues tested the drug, depsipeptide//, in patients with T-cell ...
... virus that kills at least 30 percent of its ... the globe more than two decades ago. Scientists retained ... and stored them in secure laboratories in Atlanta, Georgia, ... of many potential bioterrorism threats, but "perhaps it is ...
... warned doctors that doxycycline -- an antibiotic being prescribed ... -- can stunt fetal growth when taken by pregnant ... urged doctors to prescribe Cipro to pregnant women. The ... being overprescribed in the general population, possibly causing common ...
... drugs, statements about drug benefits are often overblown ... expected benefit; instead, they make an emotional appeal," ... New Hampshire. // ,Instead of telling ... medicine is going to prevent some outcome, these ...
Cached Medicine News:
Inquire...
Inquire...
One Pair of Knife Raising Blocks to move blade up 1 inch for adpatation of a freezing stage....
CO2 gas object holder and knife freezer for the 8000 Series Sliding Microtome...
Medicine Products: